Doctor Silvia Cantoni
R&D Chiesi Farmaceutici S.P.A., Parma (Italy)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
The selective rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates monocrotaline-induced pulmonary hypertension
Event: ESC Congress 2017
Topic: Chronic pulmonary hypertension
Session: Understanding the pulmonary circulation
Hemodynamic and anti-remodelling effect of the rho kinase inhibitor y-27632 in monocrotaline pulmonary arterial hypertension rat model
Event: ESC Congress 2016
Topic: Chronic pulmonary hypertension
Session: Basic mechanisms in pulmonary hypertension
ESC 365 is supported by
